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onverbruikte werkkragte onproduktief verlore te ien gaan
nie. Soos etie publiek an Suid-Afrika saamgestaan het om
die bedreiging van tering die hoof te bied, sal hulle weer
moet saamstaan om die bedreiging van geeste iekte af te
weer.
En wat etie mediese profes ie betref, ou dit waar kynlik
nodig wees om die aak by sy wonds aan te pak. ou dit
te veel wees om te se dat 'n ingrypende verandering teweeg-
gebring moet word ten op igte van die opleiding van mediese
tudente op hieretie gebied? Die sielkunde en die p igiatrie
was nog altyd afskeepvakkies aan die meeste van ons medie e
kole. Hieretie toestand van sake moet radikaal verander
word. Die gewone dokter as algemene prakti yn i by
uitstek die man wat uitgeru moet wees om die probleem
ertakking te kan hanteer
\ ant dan al hy--di algemene prakti yn-v eer word \ at
hy bedoel i om te wees: die voog, nie net van die liggaam-
like wel tand an die gemeen kap nie, maar ook an y
p igie " el tand.
On leef in 'n tyd wat bo alle gekenmerk word deur
ongekende panning en drukte in haa alle lewen fere.
En die atoomeeu het ons kielik tot die besef gebring dat
die ukse volle bantering, an die probleem an men Like
erhouding op die per oonlike, na ionale en interna ionale
vlakke en op etie ba i an n kerngesonde gee te ge teld-
heid, 'n onontbeerlike ver i te vir die voortbe taan an on
be ka\ ing i. DJt i die uitdaging waar oor die moderne
o iale medisyne te taan gekom het.
EDITORIAL
PSYCHOSOMlMETIC GENTS
. It has been known for centuries tbat man's behaviour can
be altered by drugs. Both acute and chronic p ychotic
states can be produced by a number of central nervou
depressants, stimulants, analgesics, autonomic drugs like
atropine and hyoscine, cocaine, and numerous others in-
cluding quinine and mepacrine, arsenic and mercur , thy-
roid, and so on. Especially in recent years, by the admini -
tration of a variety of drugs and by other procedures experi-
mental psychiatrists have sought to produce 'model' psy-
choses in animals and man that might shed some light on
conditions such as schizophrenia.! Many of the methods
used in animals have not been suitable for human experi-
mentation, and much study has therefore been made on
alterations in behaviour encountered in the course of treat-
ment or during research on other problems.
The administration of LSD 25 (lysergic acid diethylamide)
or of mescaline has' been much used to produce 'model'
psychoses, particularly for exploring the aetiology of schizo-
phrenia;- 0 simple relationship appears to exist between
'clinical' and 'model' psycboses but some features common
to both are likely to be elucidated.
The etiscovery of the mental effects of LSD 25 and an
account of the symptomatology have received wide publicity
in medical journals since the first descriptions by StoW in
1943 in Swiss literature; later in the English language by
such workers as De Shon et al.,2 Osmond and Smythie ,3
Hoch et al.,4 Isbell et al.,5 pnd Hurst et af.6· As originally
recounted by Stohl the ingestion of LSD 25 (usually 30
micrograms) produced symptoms in about t hour which
reached a peak in li- hours and completely etisappeared
by the end of 8 hours: At first such features were noted as
atoxia, dysarthria, tremor, nausea, headache, palpitations,
conjunctival injection, sweating, and deepening of respira-
tion; i.e. of a motor and autonomic nature. Later there
were marked disturbance of perception; visual hallucina-
tions were prominent with a variety of scintillations and
geometric patterns varying in design and colour and often
grotesque in nature. In ight was retained throughout re-
garding these unreal phenomena. Illusions were common,
also disturbances of taste, and of tactile and deep en ibility.
Con ciousness was never seriously eti turbed. There is a
general resemblance in the LSD-25 syndrome to that pro-
duced by mescaline, cannabi , and cocaine. In the different
descriptions given by variou in e tigator it is nece ary
to take into account such factors a do age, environmentaL
conditions, type of subject, and the object of the observer
in making the inve tigation. However, by tuetie of thi
nature some relation hip may become e ·tabli hed between
the clinicaL effects produced by these drug and their mechan-
i ms of action.
Much remain to be learned about the biochemical me-
chani ms of action of drug u ed in p ychiatry. Cerebral
glycolysi and oxidation may be affected and other metabolic
proces es which are till obscure. Very little is known about
'phy ical' action apart from metabolic action on neural
activity,7 and in addition to such mechani ms other of
neurophysiological and p ychological type may contribute
to the total pattern of drug modification of behaviour.
There are already numerous reports on the neurophy io-
logical actions of psychosomimetic drugs on the electrical
activity of the cerebral cortex, the long sen ory pathway
and the projection systems. They can profoundly affect
the patterns of afferent impul e pa ing to the cortex,
thus altering mental and motor output. europhy iological
findings have, however, not yet been sufficient to detect
the many variables influencing human behaviour.
As emphasized by Wikler,8 it matter little whether 'model'
p ychoses resemble chizophrenia. The u e of drugs as
tools to detect and manipulate the biochemical, phy iological
and psychological variables of cerebral function will make
it more pos ible to develop concepts about the dynamic
proce es underlying normal or abnormal behaviour. P y-
chiatrists and pharmacologi t will need to embark on a
joint effort in searching for 'pattem- pecificity' of drug
action, which may reveal common denominators upon
which they act, and 0 provide a means for studying theorie
of behaviour. In this way progre may be made in the
clinic and the laboratory.
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